Ranibizumab
- PDF / 169,311 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 97 Downloads / 195 Views
1 S
Acute intraocular inflammation and subconjunctival haemorrhage: 2 case reports In a retrospective study of 323 patients, who received anti-vascular endothelial growth factor injections at Hangil Eye Hospital, South Korea between January 2014 and June 2019, two patients [ages and sexes not stated] were described, who developed acute intraocular inflammation or subconjunctival haemorrhage following treatment with ranibizumab [durations of treatments to reactions onsets, doses and indications not stated]. One patient, who received bilateral intravitreal injection of ranibizumab in 2015, developed subconjunctival haemorrhage. The other patient, who received bilateral intravitreal injection of ranibizumab in 2019, developed acute intraocular inflammation. Subsequently, the patient with acute intraocular inflammation was treated with unspecified steroid eye drops. Within two weeks after administration of the ranibizumab injections, both patients showed complete improvement without any visual deterioration. Jang K, et al. Evaluation of the safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents: Experience of a large korean retina center. 803520113 Clinical Ophthalmology 14: 3211-3218, 12 Oct 2020. Available from: URL: http://doi.org/10.2147/OPTH.S276620
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
